Show simple item record

dc.contributor.advisorSchumann, Lorna
dc.creatorElsethagen, T. K.
dc.date.accessioned2012-11-06T22:06:23Z
dc.date.available2012-11-06T22:06:23Z
dc.date.issued11/6/2012
dc.identifier.urihttp://hdl.handle.net/2376/4211
dc.descriptionThesis (M.Nurs.), College of Nursing, Washington State Universityen_US
dc.description.abstractThe blood borne infectious disease hepatitis C was initially recognized in the mid-20th century. It was termed as non-A non-B hepatitis in the 1970's while scientists worked to find and map out its unique structure. It was isolated and identified in the 1980's and treated initially with interferon alfa in 1986. Since the first mono-therapy of interferon alfa, there have been increasingly more effective therapies and more knowledge created for and about this virus. The objective of this paper is to discuss recent changes to the standard of care for Hepatitis C genotype 1 based on evidence from two newly released drugs: beceprevir and telaprevir.en_US
dc.languageEnglish
dc.rightsCreative Commons Attribution-NonCommercial-ShareAlike 3.0 United States (CC BY-NC-SA 3.0 US)
dc.rights.urihttp://creativecommons.org/licenses/by-nc-sa/3.0/us
dc.titleEvidenced Based Treatment Recommendations for the Treatment of HCV Genotype 1
dc.typeElectronic Thesis or Dissertation


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

Creative Commons Attribution-NonCommercial-ShareAlike 3.0 United States (CC BY-NC-SA 3.0 US)
Except where otherwise noted, this item's license is described as Creative Commons Attribution-NonCommercial-ShareAlike 3.0 United States (CC BY-NC-SA 3.0 US)